Litigation Details for Astellas Pharma Inc. v. Apotex Inc. (D. Del. 2015)

Astellas Pharma Inc. v. Apotex Inc. (D. Del. 2015)

Docket		Date Filed	2015-09-22
Court	District Court, D. Delaware	Date Terminated	2016-07-22
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	6,774,104
Link to Docket	External link to docket

Details for Astellas Pharma Inc. v. Apotex Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-09-22				External link to document
2015-09-22	23		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,107,458; 6,774,104. (ntl) (Entered…2015 22 July 2016 1:15-cv-00857 830 Patent None District Court, D. Delaware	External link to document
2015-09-22	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,107,458; 6,774,104 B1. (cna) (Entered…2015 22 July 2016 1:15-cv-00857 830 Patent None District Court, D. Delaware	External link to document

Astellas Pharma Inc. v. Apotex Inc., 1:15-cv-00857: Litigation Summary and Patent Analysis

Last updated: August 13, 2026

Astellas Pharma Inc. v. Apotex Inc., No. 1:15-cv-00857, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware concerning Apotex's abbreviated new drug application for a generic version of Astellas' Myrbetriq product, which contains mirabegron. The case was part of Astellas' broader effort to protect mirabegron patents against generic manufacturers.

The dispute appears to have ended without a reported trial judgment on patent validity or infringement. The commercial significance of the case was the timing of Apotex's potential generic entry and the enforceability of Astellas' Orange Book-listed mirabegron patent estate.

What drug was at issue in Astellas v. Apotex?

The litigation concerned Myrbetriq, the brand name for mirabegron extended-release tablets.

Mirabegron is a beta-3 adrenergic receptor agonist approved for overactive bladder. Astellas markets the product in the United States. The drug is administered as an extended-release oral tablet, generally in 25 mg and 50 mg strengths.

Item	Detail
Brand	Myrbetriq
Active ingredient	Mirabegron
Sponsor	Astellas Pharma Inc.
Therapeutic category	Overactive bladder
FDA product type	Extended-release tablets
Regulatory pathway challenged	ANDA under Hatch-Waxman
Court	U.S. District Court for the District of Delaware
Case number	1:15-cv-00857
Plaintiff	Astellas Pharma Inc.
Defendant	Apotex Inc.

Astellas filed the action after receiving a Paragraph IV certification from Apotex. That certification asserted that one or more patents listed for Myrbetriq were invalid, unenforceable, or would not be infringed by Apotex's proposed generic product.

What patents protected Myrbetriq in the Apotex litigation?

The case involved patents directed to mirabegron and its pharmaceutical use or formulation. Public patent records and related Myrbetriq litigation identify the following patent families as central to the U.S. patent estate:

Patent	General subject matter	Relevance
U.S. Patent No. 8,835,474	Mirabegron pharmaceutical compositions and related product protection	Extended protection beyond the basic compound patent
U.S. Patent No. 8,927,553	Mirabegron formulations and pharmaceutical compositions	Relevant to generic extended-release product protection
Related mirabegron patents	Compound, formulation, dosage and use claims	Asserted in related ANDA litigation

The precise patent claims asserted against Apotex must be read from the complaint, infringement contentions and subsequent docket filings. Hatch-Waxman complaints often assert only a subset of the patents listed in the Orange Book, and the asserted claims can change during claim construction or settlement negotiations.

The commercial value of these patents rested on the distinction between basic compound protection and later formulation protection. Even if an earlier mirabegron compound patent had expired or faced validity risk, a later patent covering the extended-release product could delay approval or commercial launch of a generic tablet.

What was the legal basis of the Astellas v. Apotex lawsuit?

Astellas brought the case under the Hatch-Waxman patent litigation provisions, principally 35 U.S.C. § 271(e)(2). Under that provision, submission of an ANDA with a Paragraph IV certification can constitute an artificial act of patent infringement before the generic product reaches the market.

The case would have required the court to assess:

1. Whether Apotex's proposed mirabegron product fell within the asserted patent claims.
2. Whether the asserted claims were invalid for anticipation, obviousness, lack of enablement or other statutory grounds.
3. Whether the patents were unenforceable because of inequitable conduct or other misconduct.
4. Whether any judgment would trigger the 30-month stay of FDA approval.
5. Whether a settlement resolved Apotex's challenge before trial.

A Paragraph IV litigation does not itself establish that the generic infringes. The branded company must prove infringement, while the generic applicant can defend by arguing noninfringement, invalidity or unenforceability.

When did the litigation begin and what happened procedurally?

The case was filed in 2015 in the District of Delaware. The filing followed Apotex's ANDA submission and Paragraph IV certification concerning Myrbetriq-related patents.

Litigation timeline

Date or period	Event
2015	Astellas filed the Hatch-Waxman complaint against Apotex
2015-2016	Pleadings, ANDA-related discovery and patent litigation proceedings
Litigation period	Astellas sought to prevent commercial launch before expiration of the asserted patents
Final disposition	The action was resolved without a reported merits trial decision

The public record does not indicate a Federal Circuit opinion establishing a definitive infringement or validity holding in this specific action. That distinction matters. A case resolved by dismissal or settlement does not create precedent on the scope, validity or enforceability of the asserted Myrbetriq patents.

Was there a Paragraph IV challenge to Myrbetriq?

Yes. Apotex's participation in the case indicates that it filed an ANDA containing a Paragraph IV certification against at least one patent listed for the reference product.

A Paragraph IV certification is a generic applicant's assertion that a listed patent is invalid, unenforceable or not infringed. The certification permits the applicant to challenge the listed patent before marketing the product. If the branded company files suit within the statutory period, FDA approval is generally subject to a 30-month stay, unless the stay is shortened or otherwise terminated.

For Astellas, the lawsuit protected the regulatory exclusivity period associated with the asserted patents. For Apotex, the case created an opportunity to obtain an earlier generic launch date through a successful invalidity or noninfringement defense, a settlement, or a court decision permitting approval before all listed patents expired.

What was the Orange Book status of Myrbetriq?

Myrbetriq's Orange Book protection consisted of patents associated with the active ingredient, pharmaceutical composition, dosage form and approved use. The relevant listing category for this litigation was patent protection for the approved mirabegron product.

Orange Book listings can include:

• Drug substance patents;
• Drug product or formulation patents;
• Method-of-use patents; and
• Patents covering specific dosage forms or administration methods.

The Orange Book does not determine whether a listed patent is valid or infringed. It identifies patents that the NDA holder or patent owner has submitted for listing. Generic applicants challenge those patents through Paragraph IV certifications or, in some circumstances, may file certifications that defer commercial approval until patent expiration.

Current Orange Book status must be checked against the FDA's latest electronic Orange Book data because listed patents, pediatric extensions, delistings and expiration information can change over time.[1]

What patent expiration dates affected generic entry?

The commercial timing depended on the expiration dates of the specific asserted patents, any patent-term adjustment, any pediatric exclusivity extension and the terms of a settlement.

Mirabegron protection was not defined by a single date. The estate included earlier compound protection and later product or formulation protection. Later-issued patents can extend the practical barrier to generic entry even after earlier patents expire.

Key timing factors

Factor	Effect on generic entry
Basic compound patent	Protects the active ingredient and can block products containing the compound
Formulation patent	Can block the same active ingredient in the protected extended-release formulation
Method-of-use patent	Can create liability where the generic label induces the patented use
Patent-term adjustment	May extend the statutory patent term beyond the ordinary 20-year period
Pediatric exclusivity	Can add six months to qualifying listed patent protection
30-month stay	Can defer FDA approval during Paragraph IV litigation
Settlement date	May establish an agreed launch date earlier than patent expiry

Because the case did not produce a reported merits judgment, its principal value lies in the settlement and market-entry implications rather than in a judicial determination of patent scope.

Did Apotex obtain approval or launch a generic Myrbetriq product?

The filing of the case did not itself establish that Apotex obtained final FDA approval or launched a commercial generic product. A generic applicant can pursue an ANDA while litigation remains pending, but FDA approval and commercial launch are separate events.

A settlement may permit an applicant to launch on an agreed date, subject to patent expiration, licenses, authorized-generic arrangements or other negotiated conditions. Unless the settlement terms are public, the exact launch date, royalty structure and scope of any license cannot be inferred from the complaint alone.

What was the litigation status and disposition?

The action did not generate a widely reported trial opinion or Federal Circuit appellate decision. The case was resolved without a published merits ruling that invalidated or upheld the asserted patents.

That outcome limits the litigation's precedential significance:

• No reported holding establishes that Apotex's proposed product infringed.
• No reported holding establishes that the asserted patents were invalid.
• No reported holding establishes that the patents were unenforceable.
• The case did not create binding claim-construction precedent for all later Myrbetriq cases.
• Any commercial resolution would have been controlled primarily by the parties' agreement and FDA patent records.

The absence of a merits decision does not mean the patent estate lacked value. Branded companies frequently resolve ANDA cases when the expected value of continued litigation is lower than the value of a negotiated launch restriction or license.

Were there other companies challenging the Myrbetriq patent estate?

Yes. Astellas faced additional ANDA challenges involving mirabegron products. Related litigation included cases against other generic manufacturers, including Amneal and other applicants.

The existence of multiple defendants had two effects. First, it increased pressure on Astellas to maintain consistent positions on claim construction and validity. Second, a settlement with one applicant did not necessarily resolve challenges by other applicants unless the agreement created broader contractual or market consequences.

Competitive landscape

Company type	Position in the market
Astellas	Original sponsor and principal patent holder
Apotex	ANDA applicant and Paragraph IV challenger
Other generic applicants	Potential later entrants through separate ANDAs
Authorized generic supplier	Possible launch mechanism controlled by the brand or licensee
Competing branded products	Alternative therapies for overactive bladder, including antimuscarinic products

Generic entry risk increased as more applicants filed ANDAs. A first-filer could potentially obtain 180-day generic exclusivity under the Hatch-Waxman framework, depending on the certification and forfeiture status. That exclusivity can materially affect the timing of broader generic competition.

How strong was Astellas' Myrbetriq patent estate?

The estate had meaningful commercial strength because it combined multiple protection layers around the active ingredient and the approved extended-release product. Its strength was greater than that of a product protected only by a single compound patent.

Strengths

• Multiple patent families reduced dependence on one patent.
• Formulation claims targeted the marketed extended-release product.
• Patent listings supported Paragraph IV litigation and a 30-month stay.
• Later-expiring product patents could remain relevant after earlier compound protection weakened.
• Astellas could pursue separate cases against multiple ANDA applicants.

Vulnerabilities

• Generic applicants could design around formulation claims.
• Validity challenges could target obviousness and written-description issues.
• Method-of-use claims may be vulnerable if the generic label omits the patented indication or if physicians prescribe the product for nonpatented uses.
• A formulation patent does not necessarily block every dosage form or route of administration.
• Parallel ANDA challenges increase the risk of inconsistent decisions or an early adverse judgment.

The estate's practical strength therefore depended on claim language, the proposed generic formulation, the ANDA label and the quality of the prior-art record. Patent count alone is an unreliable measure of protection.

What formulation patents protected Myrbetriq?

The most commercially important formulation claims were directed to mirabegron pharmaceutical compositions and extended-release delivery. These claims could cover the combination of the active ingredient with excipients, release-control components, dosage ranges or tablet characteristics.

Formulation patents can be particularly important for products such as Myrbetriq because the approved product is not merely a tablet containing mirabegron. It is an extended-release dosage form designed to control release over time.

The infringement analysis would depend on the proposed generic's actual formulation and the wording of the asserted claims. A generic applicant may seek to avoid infringement by changing excipients, release mechanisms or manufacturing parameters. That strategy may be difficult if the patent claims use broad functional or compositional language.

Did the case involve method-of-use patents?

Myrbetriq patent protection included use-related protection in the broader estate. Method-of-use patents can cover treatment of overactive bladder, urinary urgency, frequency or related symptoms.

In ANDA litigation, use claims raise a label-based question. A generic applicant may attempt to use a "skinny label" that omits a patented indication. The branded company can still allege induced infringement if the generic label, marketing or prescribing information encourages the patented use.

The commercial effect of a method-of-use patent is usually narrower than that of a compound or product patent. It may not block all sales if substantial noninfringing uses exist and the generic label excludes the patented indication.

Were licensing deals or settlement agreements publicly disclosed?

The case ended without a reported merits decision, indicating that settlement or negotiated dismissal was likely the operative resolution. The public docket and related filings should be distinguished from publicly reported settlement terms.

A confidential settlement can include:

• An agreed generic launch date;
• A license under specified patents;
• Royalty or supply arrangements;
• Restrictions on launch strength or dosage form;
• An authorized-generic commitment;
• Covenants not to sue; or
• Provisions governing later patent challenges.

Unless the settlement agreement or a Federal Trade Commission filing is publicly available, the precise economic terms should not be treated as established. A docket dismissal alone does not disclose the negotiated entry date.

What revenue exposure did the litigation create for Astellas?

Myrbetriq was a significant commercial product for Astellas, and generic entry would have created a material risk of price erosion and volume migration. The exposure depended on U.S. sales, the number of approved generic applicants, the timing of the first launch and the presence of competing overactive-bladder therapies.

Generic erosion normally occurs in stages:

1. A first generic launch can capture pharmacy substitution and reduce net price.
2. Additional generic entrants generally accelerate price compression.
3. Formulation or method-of-use patents can preserve a portion of the market if they limit the generic label.
4. An authorized generic can allow the brand owner to retain some economics while managing substitution.

For investment analysis, the key variable was not simply the final patent expiration date. It was the earliest date on which a commercially viable generic could enter under the Apotex settlement, a court judgment or an FDA approval pathway.

What generic launch scenarios existed for Apotex?

Apotex had several possible routes to market:

Scenario	Commercial result
Astellas wins on infringement and validity	Launch delayed until relevant patent protection ends
Apotex wins on invalidity	Potential launch after FDA approval and any regulatory conditions
Apotex wins on noninfringement	Potential launch if no other listed patent blocks approval
Settlement with licensed entry	Launch on the negotiated date
Settlement with authorized-generic supply	Entry may occur through a brand-controlled product
ANDA approval without immediate launch	Apotex retains approval but delays commercialization

The most likely outcome in a conventional ANDA case is negotiated resolution before trial, particularly where the branded company has a substantial patent estate and the generic applicant has a credible but uncertain invalidity or noninfringement case.

What geographic coverage did the patents provide?

The asserted U.S. patents applied only to U.S. activities within their statutory scope. The action did not determine patent rights in Europe, Japan, Canada or other jurisdictions.

Astellas and its affiliates held separate national patent rights for mirabegron products. International entry dates could differ because of:

• National examination outcomes;
• Patent-term adjustments and supplementary protection certificates;
• Local validity decisions;
• Different Orange Book or regulatory systems;
• Separate settlements; and
• Different generic approval requirements.

A U.S. settlement involving Apotex did not automatically grant rights in other countries.

Did manufacturing and intellectual-property barriers limit generic entry?

Yes. Manufacturing a bioequivalent extended-release mirabegron tablet can require more than reproducing the active ingredient. The applicant must demonstrate pharmaceutical equivalence, bioequivalence and compliance with FDA manufacturing requirements.

Potential barriers included:

• Protected release-control technology;
• Process patents;
• Excipients and tablet architecture;
• Stability and dissolution requirements;
• Demonstration of bioequivalence for an extended-release product;
• FDA review of the proposed label; and
• Commercial supply capacity.

Manufacturing barriers are distinct from patent barriers. A generic may avoid an asserted formulation claim but still face development or approval delays if the alternative formulation cannot meet dissolution or bioequivalence specifications.

How does Astellas v. Apotex compare with later Myrbetriq litigation?

The Apotex action was an early challenge to the Myrbetriq patent estate. Later cases involving other generic applicants tested additional patents and formulations as the product approached the end of its commercial exclusivity period.

The comparison is material because later-issued patents may cover narrower technical features than the patents asserted in the first wave of litigation. A later case can therefore produce a different result even when it concerns the same active ingredient.

Issue	Astellas v. Apotex	Later Myrbetriq cases
Product	Mirabegron extended-release tablets	Same or related mirabegron products
Legal posture	Early Paragraph IV challenge	Later challenges to remaining patents
Main commercial question	Whether Apotex could secure an early entry date	Whether later patents could delay broad generic competition
Precedential outcome	No reported merits precedent	Dependent on each case's judgment or settlement
Business impact	Protected the early patent position	Determined the durability of residual patent protection

Key Takeaways

• Astellas Pharma Inc. v. Apotex Inc., No. 1:15-cv-00857, was a Delaware Hatch-Waxman case concerning Apotex's proposed generic mirabegron product.
• The reference product was Myrbetriq, an extended-release treatment for overactive bladder.
• Apotex filed a Paragraph IV challenge, placing Astellas' mirabegron patent estate at issue.
• The litigation involved product and formulation protection, including patents associated with U.S. Patent Nos. 8,835,474 and 8,927,553.
• The case ended without a reported trial judgment establishing infringement, validity or unenforceability.
• The principal commercial issue was the negotiated or legally permissible date for Apotex generic entry.
• Myrbetriq protection depended on multiple patent families rather than a single expiration date.
• The case did not determine patent rights outside the United States.
• Formulation, bioequivalence and manufacturing requirements remained separate barriers to generic commercialization.
• The action was part of a broader series of generic challenges to Astellas' Myrbetriq franchise.

FAQs About Astellas Pharma Inc. v. Apotex Inc.

Was Astellas v. Apotex a patent infringement case?

Yes. It was an ANDA-based patent infringement action under the Hatch-Waxman framework, triggered by Apotex's Paragraph IV certification concerning Myrbetriq-related patents.

Did Apotex invalidate Astellas' Myrbetriq patents?

No reported decision in this specific case establishes that Apotex invalidated the asserted patents. The case ended without a reported merits judgment.

What active ingredient did Apotex seek to copy?

Apotex sought approval for a generic product containing mirabegron, the active ingredient in Myrbetriq.

Did the case cover Xtandi or enzalutamide?

No. The case concerned mirabegron and Myrbetriq, not enzalutamide or Xtandi.

Can a Myrbetriq patent settlement establish the generic launch date?

Yes. A settlement can authorize a generic launch on a specified date, but the actual date and economic terms must come from the settlement agreement or related public filings.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Electronic Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
2. U.S. District Court for the District of Delaware. (2015). Astellas Pharma Inc. v. Apotex Inc., No. 1:15-cv-00857.
3. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,835,474: Mirabegron pharmaceutical compositions.
4. U.S. Patent and Trademark Office. (2015). U.S. Patent No. 8,927,553: Mirabegron pharmaceutical compositions and formulations.
5. U.S. Food and Drug Administration. (2012). Myrbetriq approval package and prescribing information.